Cell Therapeutics (CTIC) jumps 21% after its Opaxio drug for treating malignant brain cancer...


Cell Therapeutics (CTIC) jumps 21% after its Opaxio drug for treating malignant brain cancer receives the FDA's orphan-drug status, which provides the developing company with marketing, fee and tax benefits. The agency assigns the status based on the early results of a Phase II study. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs